Equity Capital Markets

Stifel ECM delivers a full suite of equity and equity linked products including IPOs, Follow-ons, Converts and SPACs across all of our focus sectors

Equity Capital Markets Group

Industry-Leading Full-Service Equity Capital Markets Group

The Equity Capital Markets Group (ECM) is responsible for originating and executing public and private equity and equity linked offerings as well as SPACs. In 2021, the ECM group managed over 265 equity and equity-linked transactions, including executing 76 IPOs, raising more than $108B. In addition, the ECM team has a leading SPAC business, advising in 2021 on more than 45 transactions within all phases of the Special Purpose Acquisition Company (SPAC) lifecycle, including IPOs, PIPEs, and de-SPAC engagements. The Stifel equity platform brings differentiated institutional access and retail distribution in the US and Internationally.

Stifel is the Leading IPO Bookrunner Among All Middle-Market or Specialist Firms

Learn More

Notable Transactions

$ 175,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2025

$ 202,000,000

Joint Bookrunning Manager

Initial Public Offering

Medtech

Mar 2025

C$ 17,400,000

Sole Bookrunner

Follow-on Offering

Metals & Mining

Feb 2025

C$ 39,005,077

Joint Bookrunner

Private Placement

Metals & Mining

Feb 2025

A$ 80,000,000

Joint Lead Arranger & Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Feb 2025

$ 384,000,000

Joint Bookrunner

Initial Public Offering

Building Products

Feb 2025

$ 219,200,000

Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2025

$ 150,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Feb 2025

$ 230,000,000

Left Bookrunner

Follow-on Offering

Energy & Natural Resources

Feb 2025

$ 75,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2025

$ 50,000,000

Joint Bookrunner

Registered Direct

Biopharma

Dec 2024

$ 257,600,000

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2024

$ 624,800,000

Joint Bookrunner

Initial Public Offering

Software

Dec 2024

$ 402,500,000

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2024

$ 115,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Aerospace, Defense & Government Services

Dec 2024

$ 196,956,533

Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Nov 2024

$ 152,500,000

Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

Nov 2024

$ 60,000,000

Joint Bookrunner & Joint Placement Agent

Registered Direct & PIPE

Biopharma

Nov 2024

$ 172,499,859

Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

Oct 2024

$ 94,500,000

Joint Bookrunner

Follow-on Offering

Real Estate

Sep 2024

$ 517,500,000

Joint Bookrunner

Follow-on Offering

Industrial & Environmental Services

Sep 2024

$ 575,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2024

$ 187,680,000

Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2024

$ 362,250,000

Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2024

$ 200,536,320

Joint Placement Agent

PIPE

Biopharma

Sep 2024

$ 258,750,000

Joint Bookrunning Manager

Follow-on Offering

Biopharma

Sep 2024

$ 200,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2024

$ 152,173,925

Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Sep 2024

$ 137,000,000

Follow-on Offering

Energy & Natural Resources

Sep 2024

$ 220,000,000

Sole Bookrunner

Initial Public Offering

Business Services

Sep 2024

$ 96,000,000

Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

Sep 2024

$ 258,750,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Aug 2024

$ 130,000,000

Joint Bookrunner

Registered Direct

Biopharma

Aug 2024

$ 33,900,000

Sole Bookrunner

Follow-on Offering

Biopharma

Aug 2024

$ 100,000,000

Lead Financial Advisor

Convertible Notes & Senior Secured Term Loan

Medtech

Aug 2024

$ 231,000,000

Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Jul 2024

$ 174,400,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2024

$ 75,000,000

Joint Bookrunning Manager

Initial Public Offering

Industrial Technology

Jun 2024

$ 155,250,000

Joint Bookrunner

Initial Public Offering

Internet & Digital Media

Jun 2024

$ 60,000,000

Joint Bookrunner

Registered Direct

Biopharma

May 2024

$ 374,325,000

Joint Bookrunner

Follow-on Offering

Biopharma

May 2024

€ 40,300,000

Joint Global Coordinator / Joint Bookrunner

Block Trade

Diversified Industries

May 2024

$ 150,000,000

Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

May 2024

$ 236,525,000

Left Bookrunner

Initial Public Offering

Transportation & Logistics

May 2024

$ 75,000,000

Sole Bookrunner

Registered Direct

Biopharma

May 2024

$ 120,000,000

Joint Bookrunner

Follow-on Offering

Engineering & Construction, and Infrastructure

Apr 2024

$ 280,000,000

Joint Placement Agent

PIPE

Biopharma

Apr 2024

$ 275,000,000

Co-Manager

Follow-on Offering

Metals & Mining

Apr 2024

$ 9,844,961

Sole Placement Agent

Registered Direct

Aerospace, Defense & Government Services

Apr 2024

$ 201,250,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2024

$ 110,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Apr 2024

C$ 23,011,788

Joint Bookrunner

Follow-on Offering

Healthcare & Special Situations

Mar 2024

$ 240,100,310

Joint Bookrunner

Registered Direct

Biopharma

Mar 2024

$ 150,000,000

Joint Bookrunner

Registered Direct

Biopharma

Mar 2024

$ 180,000,000

Joint Placement Agent

PIPE

Biopharma

Mar 2024

$ 125,000,025

Joint Bookrunner

Follow-on Offering

Electronics & Industrial Technology

Mar 2024

$ 482,999,902

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2024

$ 140,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2024

$ 632,540,250

Joint Bookrunner

Follow-on Offering

Biopharma

Feb 2024

$ 160,125,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Feb 2024

$ 57,800,000

Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Feb 2024

$ 172,800,000

Joint Bookrunner

Follow-on Offering

Real Estate

Jan 2024

$ 345,144,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2024

C$ 25,000,000

Joint Bookrunner

Private Placement

Technology

Dec 2023

$ 230,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2023

$ 20,300,000

Left Bookrunner

Registered Direct

HealthTech

Dec 2023

$ 175,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Electronics & Industrial Technology

Dec 2023

$ 180,000,000

Joint Placement Agent

PIPE

Biopharma

Dec 2023

$ 300,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Nov 2023

$ 111,536,216

Joint Bookrunner

Initial Public Offering

Biopharma

Nov 2023

$ 150,150,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Oct 2023

$ 190,000,000

Left Bookrunner

Initial Public Offering

Energy & Natural Resources

Oct 2023

$ 4,483,000,000

Financial Advisor

Has Completed a Spin-off

Capital Goods

Oct 2023

$ 100,000,000

Joint Bookrunner

Registered Direct

Biopharma

Oct 2023

$ 115,000,000

Joint Bookrunner

Confidentially marketed Follow-on Offering

Biopharma

Sep 2023

$ 250,070,000

Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2023

$ 300,000,000

Joint Bookrunner

Follow-on Offering

Restaurants

Sep 2023

$ 267,280,430

Joint Bookrunner

Private Placement

Metals & Mining

Aug 2023

$ 46,000,000

Left Bookrunning Manager

Confidentially Marketed Follow-on

Software

Aug 2023

$ 130,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jul 2023

$ 345,057,500

Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2023

£ 10,000,000

Joint Bookrunner

Equity Placing

Healthcare

Jul 2023

$ 256,000,000

Joint Bookrunning Manager

Initial Public Offering

Energy & Natural Resources

Jun 2023

$ 120,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jun 2023

$ 45,209,375

Joint Bookrunner

Follow-on Offering

Gaming & Leisure

Jun 2023

$ 365,444,420

Joint Bookrunner

Initial Public Offering

Restaurants

Jun 2023

$ 50,000,000

Sole Bookrunner

Follow-on Offering

Energy & Natural Resources

Jun 2023

$ 517,500,000

Joint Bookrunner

Follow-on Offering

Industrial & Environmental Services

Jun 2023

$ 137,200,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jun 2023

$ 34,931,250

Joint Bookrunner

Follow-on Offering

Diversified Industries

May 2023

$ 98,900,000

Joint Bookrunner

Follow-on Offering

Specialty Distribution

May 2023

$ 90,000,000

Joint Bookrunner

Follow-on Offering

Consumer Products

May 2023

£ 12,500,000

Nomad, Joint Broker and Joint Bookrunner

Equity Placing

Technology

May 2023

£ 92,000,000

Joint Bookrunner

Follow-on Offering

Diversified Industries

Apr 2023

$ 460,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2023

$ 65,000,000

Joint Bookrunner

Preferred Stock

Transportation & Logistics

Mar 2023

C$ 17,500,000

Sole Bookrunner

Follow-on Offering

Mar 2023

$ 1,220,000,000

Capital Markets Advisor

Mergers & Acquisitions

Food & Beverage

Feb 2023

$ 230,000,000

Joint Bookrunner

Follow-on Offering

Specialty Distribution, Building Products

Feb 2023

$ 163,000,000

Joint Global Coordinator and Joint Bookrunner

Follow-on Offering

Feb 2023

$ 189,400,000

Joint Bookrunner

Follow-on Offering

Real Estate

Feb 2023

$ 220,800,000

Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2023

$ 504,000,000

Advisor to Seller

Mergers & Acquisitions

Electronics & Industrial Technology

Feb 2023

$ 20,300,000

Sole Placement Agent and Nomad

PIPE

Healthcare

Feb 2023

$ 100,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Feb 2023

$ 19,940,000

Sole Bookrunner

Confidentially Marketed Follow-on Offering

Electronics & Industrial Technology

Jan 2023

$ 100,000,000

Joint Bookrunner

Initial Public Offering

Energy & Natural Resources

Jan 2023

$ 227,843,965

Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2023

$ 120,000,000

Left Bookrunner

Convertible Notes

Medtech

Dec 2022

$ 115,799,748

Joint Bookrunner & Joint Placement Agent

Registered Direct & PIPE

Biopharma

Dec 2022

$ 65,010,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2022

$ 300,375,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2022

$ 44,664,988

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Electronics & Industrial Technology

Nov 2022

$ 62,000,000

Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

Nov 2022

$ 850,000,000

Financial and Capital Markets Advisor

Mergers & Acquisitions

Biopharma

Nov 2022

$ 115,000,000

Joint Bookrunner

Follow-on Offering

Medtech

Oct 2022

£ 64,000,000

Sole Bookrunner, Sole Placement Agent, Sole Broker and Nomad

Convertible Bond & Follow-on Offering

Healthcare Services

Oct 2022

C$ 175,005,000

Co-Lead Manager

Follow-on Offering

Metals & Mining

Oct 2022

$ 75,000,000

Joint Placement Agent

Senior Secured Notes

Industrial & Environmental Services

Oct 2022

$ 80,000,000

Joint Placement Agent

PIPE

Industrial & Environmental Services

Oct 2022

£ 10,482,996

Broker and Sole Bookrunner

Placing and Subscription

Internet & Digital Media

Oct 2022

$ 220,000,000

Joint Broker and Joint Bookrunner

Follow-on Offering

Technology

Sep 2022

Joint Global Coordinator and Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Sep 2022

$ 58,079,577

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Sep 2022

$ 69,750,000

Joint Bookrunner

Follow-on Offering

Food & Beverage

Sep 2022

$ 124,800,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Sep 2022

$ 1,085,600,000

Lead Financial & Capital Markets Advisor

Business Combination

Food & Beverage

Aug 2022

$ 658,000,000

Advisor to Seller

Mergers & Acquisitions

Internet & Digital Media

Aug 2022

$ 84,309,375

Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

Aug 2022

$ 84,249,986

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Aug 2022

$ 143,893,750

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Aug 2022

$ 862,500,000

Lead Manager

Follow-on Offering

Biopharma

Aug 2022

$ 1,308,000,000

Advisor to Seller

Mergers & Acquisitions

Software

Aug 2022

$ 338,750,000

Advisor to Buyer

Mergers & Acquisitions

Software

Aug 2022

$ 181,800,000

Joint Bookrunner

Follow-on Offering

Real Estate

Aug 2022

$ 550,000,000

Advisor to Seller

Has Received a Minority Investment from

Consumer Products

Aug 2022

€ 30,000,000

Joint Global Coordinator and Euronext Growth Advisor

Initial Public Offering

Energy & Natural Resources

Jul 2022

$ 104,500,000

Sole Placement Agent

Senior Secured Term Loan

Medtech

Jul 2022

$ 55,300,000

Sole Bookrunner

Exchange of Convertible Notes

Medtech

Jul 2022

$ 250,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

HealthTech

Jun 2022

C$ 5,010,000

Left Bookrunner

Follow-on Offering

Metals & Mining

Jun 2022

C$ 7,287,000

Sole Bookrunner

Follow-on Offering

Consumer & Retail

Jun 2022

C$ 20,000,000

Left Bookrunner

Follow-on Offering

Metals & Mining

Jun 2022

C$ 17,047,000

Co-Manager

Convertible Notes

May 2022

C$ 34,511,565

Joint Bookrunner

Follow-on Offering

HealthTech

May 2022

£ 34,261,864

Joint Bookrunner

Follow-on Offering

Biopharma

May 2022

$ 108,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

May 2022

$ 350,000,000

Joint Bookrunner

Follow-on Offering

Consumer Products

May 2022

$ 200,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Apr 2022

£ 300,000,000

Sole Sponsor, Financial Adviser, Global Coordinator, Bookrunner

Follow-on Offering

Real Estate

Apr 2022

$ 230,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2022

$ 149,500,000

Joint Bookrunner

Follow-on Offering

Specialty Distribution, Building Products

Apr 2022

€ 15,000,000

Joint Global Coordinator and Joint Bookrunner

Follow-on Offering

Healthcare

Apr 2022

$ 30,000,000

Sole Financial Advisor and Sole Placement Agent

Convertible Bond and Equity Placing

Medtech

Mar 2022

$ 230,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2022

$ 75,000,000

Left Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2022

C$ 32,343,743

Joint Bookrunner

Follow-on Offering

Consumer & Retail

Mar 2022

C$ 25,311,500

Co-Manager

Follow-on Offering

Mar 2022

$ 230,000,000

Joint Bookrunner

Initial Public Offering

Capital Goods

Mar 2022

$ 1,440,000,000

Financial Advisor

SPAC Merger

Capital Goods

Feb 2022

$ 1,052,000,000

Capital Markets Advisor

Mergers & Acquisitions

Internet & Digital Media

Feb 2022

$ 85,000,000

Joint Bookrunner

Initial Public Offering

Consumer Products

Feb 2022

C$ 200,000,000

Co-Manager

Senior Notes

Feb 2022

$ 100,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jan 2022

$ 200,000,000

Joint Bookrunner

Initial Public Offering

Electronics & Industrial Technology

Jan 2022

C$ 33,532,415

Co-Manager

Follow-on Offering

Metals & Mining

Jan 2022

£ 130,000,000

Joint Bookrunner

Follow-on Offering

Diversified Industries

Jan 2022

$ 390,320,000

Joint Bookrunner

Follow-on Offering

Real Estate

Jan 2022

C$ 42,542,500

Co-Manager

Follow-on Offering

Metals & Mining

Jan 2022

$ 200,300,000

Joint Bookrunner

Follow-on Offering

Real Estate

Jan 2022

C$ 195,000,000

Advisor to the Special Committee of the Board of Fiore Gold

Fairness Opinion

Metals & Mining

Jan 2022

$ 98,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jan 2022

$ 1,500,000,000

Joint Financial Advisor

Mergers & Acquisitions

Electronics & Industrial Technology

Dec 2021

$ 70,000,000

Joint Placement Agent

PIPE

Electronics & Industrial Technology

Dec 2021

$ 200,000,000

Sole Bookrunner

SPAC IPO

Automotive Aftermarket

Dec 2021

$ 180,000,000

Joint Bookrunner

Follow-on Offering

Internet & Digital Media

Dec 2021

$ 1,239,000,000

Advisor to Seller

Mergers & Acquisitions

Electronics & Industrial Technology

Dec 2021

$ 52,325,000

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2021

$ 41,000,000

Bookrunner, Global Coordinator and Nomad

Technology

Nov 2021

C$ 230,071,000

Co-Manager

Follow-on Offering

Nov 2021

C$ 65,000,000

Co-Lead Manager

Convertible Notes

HealthTech

Nov 2021

$ 172,500,000

Left Bookrunner

SPAC IPO

Biopharma

Nov 2021

C$ 20,000,000

Sole Bookrunner

Convertible Debentures

Diversified Industries

Nov 2021

C$ 22,000,000

Sole Bookrunner

Follow-on Offering

Diversified Industries

Nov 2021

$ 105,000,000

Joint Bookrunner

Follow-on Offering

Engineering & Construction, and Infrastructure

Nov 2021

$ 72,250,000

Joint Bookrunner

Follow-on Offering

Real Estate

Nov 2021

$ 80,500,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Nov 2021

$ 43,000,000

Lead Placement Agent

Private Placement

Biopharma

Nov 2021

$ 100,800,000

Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Nov 2021

$ 300,000,000

Joint Bookrunner

Follow-on Offering

Tech-Enabled Services

Nov 2021

C$ 26,101,250

Joint Bookrunner

Follow-on Offering

Metals & Mining

Nov 2021

$ 350,000,000

Exclusive Financial Advisor & Capital Markets Advisor

Mergers & Acquisitions

Gaming & Leisure

Nov 2021

$ 450,000,000

Joint Bookrunner

Follow-on Offering

Electronics & Industrial Technology

Nov 2021

C$ 100,020,000

Sole Bookrunner

Private Placement

Technology

Nov 2021

$ 158,000,000

Capital Markets Advisor

Mergers & Acquisitions

HealthTech

Nov 2021

C$ 25,875,000

Joint Bookrunner

Follow-on Offering

Nov 2021

$ 230,000,000

Joint Bookrunner

Initial Public Offering

Healthcare Services

Nov 2021

$ 93,600,000

Joint Bookrunner

Initial Public Offering

Medtech

Oct 2021

$ 422,000,000

Joint Bookrunner

Initial Public Offering

Tech-Enabled Services

Oct 2021

$ 74,250,000

Joint Bookrunner

Follow-on Offering

Consumer Products

Oct 2021

$ 150,750,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Oct 2021

C$ 49,831,250

Left Bookrunner

Follow-on Offering

Metals & Mining

Oct 2021

£ 200,000,000

Sole Bookrunner and Financial Adviser

Follow-on Offering

Real Estate

Oct 2021

£ 50,000,000

Joint Bookrunner

Follow-on Offering

Diversified Industries

Oct 2021

C$ 7,004,400

Joint Bookrunner

Follow-on Offering

Healthcare & Special Situations

Oct 2021

$ 74,865,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Oct 2021

C$ 17,307,500

Joint Bookrunner

Follow-on Offering

Consumer & Retail

Oct 2021

C$ 5,949,680

Co-Lead Agent

Private Placement

Metals & Mining

Oct 2021

$ 165,000,000

Left Bookrunner

SPAC Initial Public Offering

Consumer Products

Oct 2021

$ 175,000,000

Sole Bookrunner

Initial Public Offering

Electronics & Industrial Technology

Oct 2021

$ 250,000,000

Joint Bookrunner

Initial Public Offering

Consumer Products

Oct 2021

$ 345,000,000

Joint Bookrunner

Follow-on Offering

Medtech

Oct 2021

C$ 173,052,000

Co-Manager

Follow-on Offering

Oct 2021

$ 195,801,300

Joint Bookrunner

Initial Public Offering

Consumer Products

Oct 2021

$ 155,000,000

Joint Bookrunner

Follow-on Offering

Engineering & Construction, and Infrastructure

Sep 2021

$ 328,600,000

Joint Bookrunner

Initial Public Offering

Tech-Enabled Services

Sep 2021

$ 410,000,000

Advisor to Seller

SPAC M&A

Electronics & Industrial Technology

Sep 2021

$ 13,200,000

Joint Bookrunner

Follow-on Offering

Healthcare Services

Sep 2021

$ 354,000,000

Joint Bookrunner

Follow-on Offering

Technology

Sep 2021

$ 1,000,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2021

£ 125,000,000

Joint Bookrunner and Financial Adviser

Follow-on Offering

Real Estate

Sep 2021

$ 651,000,000

Capital Markets Advisor

SPAC Merger

Tools & Diagnostics

Sep 2021

C$ 108,150,000

Co-Manager

Follow-on Offering

Aug 2021

$ 4,100,000,000

Capital Markets Advisor

Has Merged with

Aerospace, Defense & Government Services

Aug 2021

$ 212,000,000

Capital Markets Advisor

SPAC Merger & PIPE

Biopharma

Aug 2021

$ 355,810,000

Joint Bookrunner

Initial Public Offering

Biopharma

Aug 2021

$ 84,333,337

Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2021

$ 424,000,000

Joint Bookrunner

Initial Public Offering

Consumer Products

Jul 2021

$ 42,000,000

Joint Bookrunner

Initial Public Offering

Gaming & Leisure

Jul 2021

$ 230,000,000

Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Jul 2021

£ 17,000,000

Sole Global Coordinator, Joint Bookrunner & Nomad

Initial Public Offering

HealthTech

Jul 2021

$ 174,560,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2021

$ 1,664,000,000

Financial Advisor and Capital Markets Advisor

Mergers & Acquisitions

Electronics & Industrial Technology

Jul 2021

$ 2,642,000,000

Capital Markets Advisor

Mergers & Acquisitions

Specialty Distribution

Jul 2021

$ 180,132,080

Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Jul 2021

$ 62,675,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Jul 2021

$ 100,190,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jul 2021

$ 350,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jul 2021

$ 325,000,000

Joint Bookrunner

Initial Public Offering

Software

Jul 2021

$ 97,807,500

Joint Bookrunner

Initial Public Offering (U.S. Nasdaq)

Medtech

Jul 2021

$ 160,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2021

$ 409,200,000

Joint Bookrunner

Initial Public Offering

Internet & Digital Media

Jun 2021

$ 409,200,000

Joint Bookrunner

Initial Public Offering

Internet & Digital Media

Jun 2021

$ 100,000,000

Left Bookrunner

Preferred Stock

Real Estate

Jun 2021

$ 160,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2021

$ 80,000,000

Left Bookrunner

Follow-on Offering

Entertainment

Jun 2021

$ 150,000,000

Sole Bookrunner

Initial Public Offering

Entertainment

Jun 2021

$ 128,600,000

Joint Global Coordinator and Joint Bookrunner

Initial Public Offfering

Internet & Digital Media

Jun 2021

$ 400,000,000

Co-Manager

Senior Notes

Jun 2021

$ 249,700,000

Joint Bookrunner

Follow-on

Consumer Products

Jun 2021

$ 96,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Electronics & Industrial Technology

Jun 2021

C$ 100,000,000

Co-Lead Manager

Follow-on Offering

Jun 2021

C$ 20,000,000

Sole Bookrunner

Follow-on Offering

Jun 2021

C$ 6,000,000

Joint Bookrunner

Private Placement

Jun 2021

$ 49,840,000

Joint Bookrunner

Follow-on Offering

Real Estate

Jun 2021

C$ 46,004,990

Sole Bookrunner

Follow-on Offering

Consumer Products

May 2021

$ 225,000,000

Joint Global Coordinator

Follow-on Offering

May 2021

C$ 175,000,000

Joint Bookrunner

Follow-on Offering

Real Estate

May 2021

C$ 201,254,750

Co-Manager

Follow-on Offering

May 2021

C$ 75,000,000

Joint Bookrunner

Follow-on Offering

Building Products

Apr 2021

$ 98,325,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2021

$ 100,912,500

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Apr 2021

$ 72,680,000

Left Bookrunner

Initial Public Offering

Packaging, Specialty Distribution

Apr 2021

Joint Bookrunner

Follow-on Offering

Real Estate

Apr 2021

$ 287,500,000

Joint Bookrunner

Follow-on Offering

Biopharma

Apr 2021

$ 177,023,991

Joint Bookrunner

Follow-on Offering

Real Estate

Apr 2021

$ 646,875,000

Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Apr 2021

$ 550,000,000

Joint Bookrunner

Convertible Senior Notes

Biopharma

Apr 2021

£ 7,454,727

NOMAD and Sole Bookrunner

Follow-on Offering

Software

Mar 2021

$ 103,500,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

$ 50,652,000

Left Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

$ 30,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

$ 75,000,000

Left Bookrunner

Preferred Stock

Mar 2021

$ 48,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2021

$ 56,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

$ 99,750,000

Joint Bookrunner

Follow-on Offering

Real Estate

Mar 2021

$ 160,425,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2021

$ 138,250,000

Sole Bookrunner

Convertible Notes

Medtech

Mar 2021

$ 42,000,000

Sole Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Feb 2021

$ 512,000,000

Co-Manager

Initial Public Offering

Financial Institutions & Financial Technology

Jan 2021

$ 400,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Metals & Mining

Jan 2021

$ 210,000,000

Sole Placement Agent

Private Placement

Real Estate

Dec 2020

$ 323,250,000

Joint Placement Agent

Private Investment in Public Equity

Electronics & Industrial Technology

Dec 2020

$ 276,000,000

Joint Bookrunner

Initial Public Offering

Software

Dec 2020

$ 555,450,000

Joint Bookrunner

Initial Public Offering

Biopharma

Dec 2020

Joint Bookrunner

Initial Public Offering

Cannabis

Dec 2020

$ 172,500,000

Joint Bookrunner

Follow-on Offering

Cannabis

Dec 2020

$ 275,000,000

Joint Bookrunner

Initial Public Offering

Software

Dec 2020

$ 56,600,000

Joint Bookrunner

Block Trade

Dec 2020

$ 45,325,000

Left Bookrunner

Block Trade

Dec 2020

$ 200,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2020

$ 345,080,500

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2020

$ 312,225,000

Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Dec 2020

$ 750,000,000

Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Dec 2020

$ 277,725,000

Joint Bookrunner

Initial Public Offering

Biopharma

Dec 2020

€ 134,071,417

Joint Bookrunner

Follow-on Offering

Industrial & Environmental Services

Nov 2020

$ 93,987,050

Left Bookrunner

Initial Public Offering

Gaming & Leisure

Nov 2020

$ 68,425,000

Joint Bookrunner

Follow-on Offering

Electronics & Industrial Technology

Nov 2020

$ 151,250,000

Joint Bookrunner

Follow-on Offering

Food & Beverage

Nov 2020

€ 30,000,000

Joint Bookrunner

Follow-on Offering

Business Services

Nov 2020

$ 333,500,000

Joint Bookrunner

Follow-on Offering

Gaming & Leisure

Nov 2020

$ 1,863,000,000

Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Nov 2020

$ 81,176,464

Joint Bookrunner

Initial Public Offering

Biopharma

Nov 2020

C$ 263,128,000

Co-Manager

Initial Public Offering

Oct 2020

$ 55,000,000

Joint Bookrunner

Follow-on Offering

Real Estate

Oct 2020

$ 345,000,000

Lead Manager

Initial Public Offering

Medtech

Oct 2020

Co-Lead Manager

Follow-on Offering

Cannabis

Jun 2020

$ 79,347,051

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2020

$ 35,000,000

Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Mar 2016

Currency volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp.